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HIV-­‐1	   establishes	   a	   latent	   infection	   that	   is	   inaccessible	   to	   treatment	   in	   cellular	   and	  
anatomical	   reservoirs.	   This	   thesis	   concerns	   several	   problematic	   issues	   of	   HIV-­‐1	  
persistence,	   including	   ways	   to	   measure	   and	   monitor	   both	   the	   virus	   at	   low	   viral	  
concentrations	   and	   the	   depletion	   of	   the	   reservoir.	   Since	   the	   central	   nervous	   system	  
(CNS)	   is	   a	   potentially	   important	   anatomical	   reservoir,	   we	   also	   explore	   the	   extent	   of	  
neurological	  injury	  in	  HIV-­‐1	  disease.	  
	  
Results	  from	  a	  previous	  study	  indicate	  that	  the	  reservoir	  in	  resting	  memory	  CD4+	  T-­‐cells	  
and	  levels	  of	  residual	  viremia	  was	  reduced	  through	  intravenous	  immunoglobulin	  (IVIG)	  
treatment	  given	  to	  patients	  on	  combination	  antiretroviral	  therapy	  (cART).	  We	  analyzed	  
T-­‐cell	  activation	  markers	  and	  potential	  long-­‐term	  effects	  of	  IVIG	  on	  residual	  viremia.	  We	  
found	   no	   lasting	   effect	   on	   residual	   viremia,	   indicating	   that	   the	   effect	   of	   IVIG	   was	  
transient.	  Activation	  markers	  and	  interleukins	  were	  not	  correlated	  to	  levels	  of	  residual	  
viremia.	  
	  
Correct	  measurements	  of	  residual	  viremia	  and	  of	  the	  reservoir	  size	  are	  crucial	  in	  HIV-­‐1	  
eradication	  trials	  and	  may	  have	  other	  clinical	  utility.	  The	  methods	  employed	  need	  to	  be	  
sensitive	  and	  subtype	  independent.	  We	  evaluated	  a	  modification	  of	  the	  COBAS	  TaqMan	  
HIV-­‐1	  test,	  version	  2.0	  and	  a	  polymerase	  chain	  reaction	  (PCR)	  assay	  for	  total	  HIV-­‐1	  DNA.	  
We	  achieved	  a	  sensitive	  quantification	  of	  plasma	  HIV-­‐1	  RNA	  that	  could	  be	  used	  to	  assess	  
residual	   viremia.	   Sensitive	   quantification	   of	   total	   HIV-­‐1	   DNA	   in	   peripheral	   blood	  
mononuclear	  cells	  was	  demonstrated	  and	  both	  assays	  were	  subtype	  independent.	  
	  
Low	   level	   viremia	   in	   patients	   on	   cART,	   defined	   as	   a	   residual	   viral	   load	   of	   20–1000	  
copies/ml	  is	  associated	  with	  increased	  risk	  of	  virologic	  failure.	  We	  evaluated	  a	  method	  
used	  for	  sequencing	  in	  the	  case	  of	  low	  level	  viremia.	  The	  method	  was	  sensitive	  and	  also	  
subtype	  independent,	  a	  feature	  making	  it	  useful	  in	  clinical	  settings	  where	  a	  diversity	  of	  
subtypes	  is	  present.	  
	  
HIV-­‐1	  establishes	  a	  chronic	  infection	  that	  also	  infiltrates	  the	  CNS	  and	  carries	  the	  risk	  of	  
developing	  neurological	  symptoms.	  By	  measuring	  neurofilament	  light	  protein	  (NFL)	  and	  
markers	   of	   inflammation	   in	   cerebrospinal	   fluid	   (CSF),	   we	   wished	   to	   determine	   the	  
extent	   of	   neurological	   injury	   and	   neuropathogenesis	   in	   HIV-­‐1	   disease.	   We	   found	  
increased	   CSF	   NFL	   both	   in	   patients	   with	   neurological	   symptoms	   and	   in	  
neuroasymptomatic	  patients.	  Treatment	  decreased	  these	  levels,	  but	  treated	  patients	  still	  
retained	  higher	  levels	  than	  controls,	   indicating	  either	  continued	  virus-­‐related	  injury	  or	  
an	  aging-­‐like	  effect	  of	  HIV-­‐1	  infection.	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